Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 21Active not recruiting 20Completed 8Terminated 2Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 11Nivolumab 6fludarabine phosphate 5fludarabine 5Paclitaxel 5Cyclophosphamide 5Cisplatin 5Cetuximab 5Carboplatin 5atezolizumab 4Specimen Handling 4Pemetrexed 4Docetaxel 4Bevacizumab 4durvalumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3venetoclax 2temsirolimus 2niraparib 2ibrutinib 2enzalutamide 2encorafenib 2binimetinib 2Trastuzumab 2Taxes 2Standard of Care 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Cytarabine × 30 days × Clear all
NCT05712278 2026-06-05

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Sanofi

Phase 1 Terminated
7 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04250051 2026-06-01

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Northwestern University

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡